Team:Freiburg/Project
From 2012.igem.org
Project
Overall project
Since April 2012, we are working in the field of so called TAL effectors in our lab. TAL effectors are molecular components that are fused to DNA binding proteins in order to restrict their acticvity to specific loci in a genome. In particular, we develop a strategy to cheaply create novel TAL effectors in an extremely short period of time. This new method will enable us to test numerous novel effectors in human cells and to assess their therapeutic potential for genetic diseases, epigenetic alterations and cancer.
We hope you will learn something about our project and the power of TAL effectors.
1. Building the Toolkit
Learn about the theory behind the TAL effector toolkit, how we created it and why we choose this design.
2. Using the Toolkit
Create your own is the inoffical motto of our toolkit. Team freiGEM knows how to use it, but Team freiGEM
wants you to know it.
Read this instruction and start working with the toolkit yourself.
3. The future of TAL
TAL effectors are so new that we cant even talk about a history of TAL, but we should talk about
their future. Our toolkit is not just easy to use but also its easy to automatable, we can proof that our kit is
easiely workable by a robot
4. The TAL Vektor
Targeting a sequence and not doing something to it, is like throwing mechanics at your car. Your car will
not get any better only the mechanics will get mad. Because we know this, we bring you the tools you
need to actually work with DNA.To make it even more easy these tools are deliverd already inside the
final TAL backbone, just add the sequence and you're ready.
5. Experiments
What is building without testing, and the mother of all tests is the biological experiment.
You dont believe in our kit like we do? Look how we tested it, get inside on the experiment design and the
theory behind the methods.
6. Results
Where is the proof? Here is the proof! Get data on our toolkit, learn how to read sequencing
and see the results of trials with the toolkit.